# Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

> **NCT05754502** · — · UNKNOWN · sponsor: **Consorzio Oncotech** · enrollment: 300 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab emtansine

## Key facts

- **NCT ID:** NCT05754502
- **Lead sponsor:** Consorzio Oncotech
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-27
- **Primary completion:** 2024-09-21
- **Final completion:** 2025-05-02
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05754502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05754502, "Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05754502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*